Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation. Blood Adv. 2023.
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021.
Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020.
HEMATOPOIETIC CELL TRANSPLANTATION IS FEASIBLE IN PATIENTS WITH PRIOR COVID-19 INFECTION. Transplant Cell Ther. 2021.
Measurement of the DNA alkylating agents busulfan and melphalan in human plasma by mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1125:121711..
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med. 2020;382(9):822-834.
Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel (tisa-cel) Recipients for B Cell Non-Hodgkin Lymphoma. Transplant Cell Ther. 2023.
Patient-Reported Outcomes with Chimeric Antigen Receptor-T Cell Therapy: Challenges and Opportunities. Biol Blood Marrow Transplant. 2018..
A Phase 2 Study of pembrolizumab after Autologous Stem Cell Transplantation in Patients with T-Cell non-Hodgkin Lymphoma. Blood. 2023.
Relapse after allogeneic stem cell transplantation of acute myeloid leukemia and myelodysplastic syndrome and importance of second cellular therapy. Transplant Cell Ther. 2021.
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity 1 with Novel Induction Regimens in Multiple Myeloma. Biol Blood Marrow Transplant. 2020.